Denali Therapeutics Inc (NASDAQ: DNLI) is 11.32% higher on its value in year-to-date trading and has touched a low of $14.56 and a high of $25.25 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The DNLI stock was last observed hovering at around $25.00 in the last trading session, with the day’s loss setting it -1.11%.
Currently trading at $23.89, the stock is 3.05% and 5.83% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.8 million and changing -4.44% at the moment leaves the stock 20.35% off its SMA200. DNLI registered 2.97% gain for a year compared to 6-month gain of 41.95%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 1.19% loss in the last 1 month and extending the period to 3 months gives it a 19.09%, and is 0.93% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.27% over the week and 5.39% over the month.
Denali Therapeutics Inc (DNLI) has around 445 employees, a market worth around $3.42B and $1.27M in sales. Profit margin for the company is -33121.86%. Distance from 52-week low is 64.08% and -5.39% from its 52-week high. The company has generated returns on investments over the last 12 months (-29.39%).
The EPS is expected to shrink by -143.80% this year
301.0 institutions hold shares in Denali Therapeutics Inc (DNLI), with institutional investors hold 104.66% of the company’s shares. The shares outstanding are 138.39M, and float is at 119.04M with Short Float at 6.04%. Institutions hold 90.39% of the Float.
The top institutional shareholder in the company is BAILLIE GIFFORD & CO with over 13.76 million shares valued at $319.59 million. The investor’s holdings represent 9.2123 of the DNLI Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 13.17 million shares valued at $305.91 million to account for 8.8181 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 11.31 million shares representing 7.5717 and valued at over $262.67 million, while WELLINGTON MANAGEMENT GROUP LLP holds 6.5753 of the shares totaling 9.82 million with a market value of $228.11 million.
Denali Therapeutics Inc (DNLI) Insider Activity
The most recent transaction is an insider sale by Watts Ryan J., the company’s President and CEO. SEC filings show that Watts Ryan J. sold 2,260 shares of the company’s common stock on Aug 20 ’24 at a price of $23.79 per share for a total of $53765.0. Following the sale, the insider now owns 0.24 million shares.
Denali Therapeutics Inc disclosed in a document filed with the SEC on Aug 20 ’24 that Krognes Steve E. (Director) sold a total of 1,727 shares of the company’s common stock. The trade occurred on Aug 20 ’24 and was made at $23.79 per share for $41085.0. Following the transaction, the insider now directly holds 32677.0 shares of the DNLI stock.
Still, SEC filings show that on Aug 20 ’24, Schuth Alexander O. (COFO and Secretary) disposed off 5,806 shares at an average price of $23.65 for $0.14 million. The insider now directly holds 180,613 shares of Denali Therapeutics Inc (DNLI).
